Skip to main content

Table 7 Estimated costs and cost-effectiveness ratios of inhaled oxytocin introduction in each setting from a societal perspective and over a lifetime horizon, 3% discount rate

From: Cost-effectiveness of inhaled oxytocin for prevention of postpartum haemorrhage: a modelling study applied to two high burden settings

  Bangladesh Ethiopia
Status quo Intervention Incremental Status quo Intervention Incremental
Costs, $000
Intervention start-up costsa   955 955   1308 1308
On-going PPH preventionb 783 985 202 840 1108 268
PPH treatment 52,479 50,606 − 1873 31,141 31,007 − 134
Total costs 53,262 52,546 − 716 31,981 33,423 1443
ICERs
$ per PPH case averted   Cost-saving    464  
$ per maternal death averted   Cost-saving    47,557  
$ per maternal life year saved   Cost-saving    1880  
$ per maternal and child life year saved   Cost-saving    1005  
ICERs (ongoing costs only)
$ per PPH case averted   Cost-saving    43  
$ per maternal death averted   Cost-saving    4435  
$ per maternal life year saved   Cost-saving    175  
$ per maternal and child life year saved   Cost-saving    94  
  1. Societal costs include public and private sector costs, and household medical and direct non-medical out of pocket costs in public and private sectors
  2. ICER incremental cost-effectiveness ratio, PPH postpartum haemorrhage
  3. aTraining and advocacy costs
  4. bCommodity (uterotonics), disposal and wastage costs